Caidya
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Caidya - overview
Established
2003
Location
Raleigh, NC, US
Primary Industry
Pharmaceuticals
About
Founded in 2003 and based in Shanghai, dMed / Clinipace is a clinical contract research organization company that provides clinical research innovative solutions to patients. It has more than 1,600 employees from 22 countries. Dr. Lingshi Tan, the current chairman and CEO of dMed, will serve as the company’s global CEO, while current Clinipace CEO Mr.
Jason Monteleone will serve as Chief Business & Strategy Officer. The company was recognized as a Top 10 Clinical Trial Services Company in Asia Pacific in 2018. In 2022, the company name changed into Caidya. In April 2021, Clinipace Inc.
and dMed Biopharmaceutical Co. , Ltd. agreed to merge to form dMed / Clinipace. The company's main business category is personalized clinical research services, which are organized into four major steps: clinical development, clinical operations and delivery, supervision, and experimental data and technology.
Its services cover North America, Asia Pcific Europe and Latin America. The company's business have served conditions including respiratory, neurological, cardiac, rare diseases, and tumors.
Current Investors
Morgan Stanley Investment Management, Hong Shan, Legend Capital
Primary Industry
Pharmaceuticals
Sub Industries
Healthcare IT, Specialty Pharmaceuticals, Pharmaceutical Research & Development
Website
www.caidya.com/
Verticals
HealthTech
Company Stage
Merged
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.